Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
Ribavirin, a nucleoside analog, is administered in combination with interferon to patients with chronic hepatitis C. To evaluate the feasibility of ribavirin therapeutic drug monitoring, we investigated the influence of blood collection and preanalytical conditions on ribavirin concentrations and compared the results obtained from interlaboratory blind tests by 3 laboratories using different analytical techniques. On 3 occasions, blank serum samples spiked with ribavirin and pooled serum samples from patients on ribavirin were sent to the 3 laboratories. Two analytical techniques were based on liquid chromatography with tandem mass spectrometry (LC-MS/MS) and 1 on high-performance liquid chromatography with UV detection (HPLC-UV), with protein precipitation or solid-phase extraction, all validated according to international guidelines. Inter- and intra-batch mean relative errors ranged from -7.4% to +10.3% and from -10.3% to +7.4%, respectively. Relative standard deviations were <13.5% and <10.6%, respectively. Linearity, assessed blindly, between 125 and 4550 ng/mL was excellent (r > 0.991) for all 3 methods. The 2 LC-MS/MS techniques were slightly less precise and accurate than HPLC-UV, perhaps because the internal standard used was not a ribavirin isotope. Accurate and precise LC-MS/MS and HPLC-UV methods developed in 3 different laboratories provided excellent and consistent results to blind tests for ribavirin determination in spiked serum samples and pools of serum samples from patients with chronic hepatitis C virus infection.
Sauvage
Francois-Ludovic
FL
INSERM U850, Univ Limoges, CHU Limoges, Service de Pharmacologie et Toxicologie, Pharmacovigilance, Limoges Cedex 87042, France.
Stanke-Labesque
Francoise
F
Gagnieu
Marie-Claude
MC
Jourdil
Jean-Francois
JF
Babany
Gerard
G
Marquet
Pierre
P
D000998:Antiviral Agents / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D016903:Drug Monitoring; D004355:Drug Stability; D005240:Feasibility Studies; D016174:Hepacivirus / Q000187:drug effects / Q000254:growth & development; D006526:Hepatitis C / Q000188:drug therapy / Q000378:metabolism*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D012254:Ribavirin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D021241:Spectrometry, Mass, Electrospray Ionization
D000998:Antiviral Agents; D012254:Ribavirin